BiomX addresses unusual stock trading activity

BiomX Inc. (NYSE American: PHGE) issued a statement regarding recent unusual trading activity in its common stock. The clinical-stage company, which develops phage therapies targeting pathogenic bacteria, said it is not aware of any material developments in its business that have not been previously disclosed.

The company stated it does not know of any reason that would account for the recent unusual market activity in its stock. NYSE American LLC contacted BiomX in accordance with its usual practice and advised the company to issue the statement.

BiomX said it does not intend to make further comments on market speculation or trading activity. The company is based in Ness Ziona, Israel, and focuses on developing natural and engineered phage cocktails for treating chronic diseases.

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• Nu Skin EVP of global sales takes medical leave
• Lazard Global Total Return fund declares $0.1534 monthly distribution